Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY24 results · Apr–Jun 2023
Glenmark Pharmaceuticals reported revenue from operations of ₹3,401.60 crore (up 22.5% from Q1 FY23) and net profit of ₹173.13 crore (down 18.0% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,401.60 | 2,777.29 | +22.5% | 3,373.72 | +0.8% |
| Other income | 20.87 | 183.16 | −88.6% | (40.21) | Turned profit |
| Total income | 3,422.47 | 2,960.44 | +15.6% | 3,333.50 | +2.7% |
| Profit before tax | 333.41 | 408.01 | −18.3% | (490.77) | Turned profit |
| Net profit for the period | 173.13 | 211.11 | −18.0% | (403.14) | Turned profit |
| Attributable to shareholders of the company | 23.19 | 192.53 | −88.0% | — | — |
| EPS, basic (₹) | 5.31 | 6.82 | −22.1% | (15.18) | Turned profit |
| Net margin (%) | 5.1 | 7.6 | -11.9 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,144.38 | 1,911.93 | +12.2% | 1,939.05 | +10.6% |
| Other income | 49.36 | 346.52 | −85.8% | 232.97 | −78.8% |
| Total income | 2,193.74 | 2,258.45 | −2.9% | 2,172.01 | +1.0% |
| Profit before tax | 392.04 | 695.55 | −43.6% | (313.32) | Turned profit |
| Net profit for the period | 271.66 | 492.58 | −44.9% | (137.47) | Turned profit |
| EPS, basic (₹) | 9.63 | 17.46 | −44.8% | (4.87) | Turned profit |
| Net margin (%) | 12.7 | 25.8 | -7.1 |
Consolidated
- Filed with BSE
- 11 Aug 2023, 19:50 IST
- Board meeting
- 11 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2023, 19:50 IST
- Board meeting
- 11 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE